Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
Multiple sclerosis
age
disease progression
magnetic resonance imaging
phenotypes
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
pubmed:
29
1
2021
medline:
28
1
2022
entrez:
28
1
2021
Statut:
ppublish
Résumé
The Oxford Big Data Institute, multiple sclerosis (MS) physicians and Novartis aim to address unresolved questions in MS with a novel comprehensive clinical trial data set. The objective of this study is to describe the Novartis-Oxford MS (NO.MS) data set and to explore the relationships between age, disease activity and disease worsening across MS phenotypes. We report key characteristics of NO.MS. We modelled MS lesion formation, relapse frequency, brain volume change and disability worsening cross-sectionally, as a function of patients' baseline age, using phase III study data (≈8000 patients). NO.MS contains data of ≈35,000 patients (>200,000 brain images from ≈10,000 patients), with >10 years follow-up. (1) Focal disease activity is highest in paediatric patients and decreases with age, (2) brain volume loss is similar across age and phenotypes and (3) the youngest patients have the lowest likelihood (<25%) of disability worsening over 2 years while risk is higher (25%-75%) in older, disabled or progressive MS patients. Young patients benefit most from treatment. NO.MS will illuminate questions related to MS characterisation, progression and prognosis. Age modulates relapse frequency and, thus, the phenotypic presentation of MS. Disease worsening across all phenotypes is mediated by age and appears to some extent be independent from new focal inflammatory activity.
Sections du résumé
BACKGROUND
The Oxford Big Data Institute, multiple sclerosis (MS) physicians and Novartis aim to address unresolved questions in MS with a novel comprehensive clinical trial data set.
OBJECTIVE
The objective of this study is to describe the Novartis-Oxford MS (NO.MS) data set and to explore the relationships between age, disease activity and disease worsening across MS phenotypes.
METHODS
We report key characteristics of NO.MS. We modelled MS lesion formation, relapse frequency, brain volume change and disability worsening cross-sectionally, as a function of patients' baseline age, using phase III study data (≈8000 patients).
RESULTS
NO.MS contains data of ≈35,000 patients (>200,000 brain images from ≈10,000 patients), with >10 years follow-up. (1) Focal disease activity is highest in paediatric patients and decreases with age, (2) brain volume loss is similar across age and phenotypes and (3) the youngest patients have the lowest likelihood (<25%) of disability worsening over 2 years while risk is higher (25%-75%) in older, disabled or progressive MS patients. Young patients benefit most from treatment.
CONCLUSION
NO.MS will illuminate questions related to MS characterisation, progression and prognosis. Age modulates relapse frequency and, thus, the phenotypic presentation of MS. Disease worsening across all phenotypes is mediated by age and appears to some extent be independent from new focal inflammatory activity.
Identifiants
pubmed: 33507835
doi: 10.1177/1352458520988637
pmc: PMC8564259
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2062-2076Références
Lancet. 2018 Mar 31;391(10127):1263-1273
pubmed: 29576505
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):93-9
pubmed: 25904813
JAMA Neurol. 2013 Feb;70(2):214-22
pubmed: 23407713
PLoS One. 2017 Apr 5;12(4):e0174866
pubmed: 28379999
J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1368-74
pubmed: 18535026
Curr Opin Neurol. 2019 Jun;32(3):365-377
pubmed: 30985372
Clin Pharmacol Ther. 2020 Apr;107(4):806-816
pubmed: 31725899
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Ann Intern Med. 2011 Jul 5;155(1):61-2
pubmed: 21727295
J Neuroimaging. 2019 Jul;29(4):527-535
pubmed: 31074192
PLoS One. 2020 May 26;15(5):e0233575
pubmed: 32453803
Mult Scler. 2007 May;13(4):509-16
pubmed: 17463073
Mult Scler. 2018 Oct;24(11):1469-1484
pubmed: 28799444
Brain. 2006 Mar;129(Pt 3):606-16
pubmed: 16415308
Mult Scler. 2017 Apr;23(5):656-664
pubmed: 27411701
Neurology. 2019 Jun 11;92(24):e2764-e2773
pubmed: 31092624
Mult Scler. 2017 Apr;23(5):647-655
pubmed: 27481209
Lancet Neurol. 2020 Apr;19(4):307-316
pubmed: 32199096
Nat Neurosci. 2016 Nov;19(11):1523-1536
pubmed: 27643430
Mult Scler Relat Disord. 2014 Mar;3(2):186-93
pubmed: 25878006
Mult Scler. 2016 Nov;22(13):1750-1758
pubmed: 26869531
Neurology. 2010 Jun 8;74(23):1868-76
pubmed: 20530323
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Nat Rev Neurol. 2017 Feb;13(2):105-118
pubmed: 28084327
Arch Neurol. 2006 Dec;63(12):1686-91
pubmed: 17172607
JAMA Neurol. 2020 Sep 1;77(9):1132-1140
pubmed: 32511687
Radiology. 2010 Feb;254(2):541-50
pubmed: 20093525
Ageing Res Rev. 2018 Jan;41:64-81
pubmed: 29101043
Mult Scler. 2020 Jan;26(1):23-37
pubmed: 31778094
Mult Scler. 2018 Oct;24(11):1485-1498
pubmed: 28847219
Eur J Neurol. 2020 Jun;27(6):1066-1075
pubmed: 32097512
Front Neurol. 2017 Nov 10;8:577
pubmed: 29176956
Mult Scler J Exp Transl Clin. 2018 May 25;4(2):2055217318778610
pubmed: 29854416